% | $
Quotes you view appear here for quick access.

Dendreon Anonim Ortaklik Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • be_careful_outdere be_careful_outdere Apr 3, 2009 3:33 PM Flag

    Novartis, Pfizer received 'Late Breaker' prior to approval

    Adam Feuerstein
    Re: Dendreon
    4/3/2009 3:26 PM EDT

    James – Dendreon secured a late-breaker presentation slot for the Provenge study at the American Urological Association annual meeting, April 25-30.

    A late-breaker presentation is offered for clinical trials or other research that are completed and submitted after the deadline for regular abstract submission is passed. While late-breaker presentation slots are usually reserved for important or high-profile research, they ARE NOT reserved solely for positive research. I have personally sat through many late-breaker presentations of failed clinical trials. In science, you can often learn as much from failure as you can from success, so medical meetings do not shy away from discussing negative data. (Or at least good medical meetings don't do that.)

    Since we already know that the Provenge data will be released later this month, the fact that the results will be presented at a scientific meeting at the end of the month doesn't tell you a whole lot about whether Provenge works or not.